1 week Ago By ABMN Staff
UiPath Inc. ( NYSE:PATH – Get Free Report ) has been given an average rating of “Hold” by the eighteen brokerages that are presently covering the company, Marketbeat Ratings reports. Sixteen equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company.
The average 1-year price target among analysts that have issued ratings on the stock in the last year is $17.71. PATH has been the topic of several research analyst reports.
Royal Bank of Canada restated a “sector perform” rating and issued a $16.00 price objective on shares of UiPath in a research report on Friday. BMO Capital Markets raised their price objective on shares of UiPath from $14.
00 to $15.00 and gave the company a “market perform” rating in a research report on Friday. Bank of America upped their target price on shares of UiPath from $16.
00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday. TD Cowen lowered their price target on UiPath from $17.
00 to $16.00 and set a “hold” rating on the stock in a research report on Friday. Finally, JPMorgan Chase & Co.
cut their price objective on UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a report on Thursday, May 30th.
Get Our Latest Stock Analysis on UiPath UiPath Price Performance UiPath ( NYSE:PATH – Get Free Report ) last issued its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.
03 by $0.01. UiPath had a negative return on equity of 2.
97% and a negative net margin of 6.41%. The company had revenue of $316.
00 million for the quarter, compared to the consensus estimate of $303.69 million. During the same quarter last year, the business posted ($0.
09) earnings per share. The firm’s revenue was up 10.0% compared to the same quarter last year.
On average, research analysts anticipate that UiPath will post -0.22 EPS for the current year. Hedge Funds Weigh In On UiPath A number of hedge funds and other institutional investors have recently made changes to their positions in the business.
Mark Sheptoff Financial Planning LLC purchased a new position in shares of UiPath during the fourth quarter valued at about $25,000. ORG Partners LLC boosted its holdings in shares of UiPath by 875.6% during the 1st quarter.
ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after buying an additional 1,112 shares in the last quarter. Hantz Financial Services Inc. purchased a new stake in shares of UiPath in the 2nd quarter worth about $28,000.
Redwood Wealth Management Group LLC bought a new position in shares of UiPath in the 2nd quarter worth about $43,000. Finally, Lindbrook Capital LLC boosted its stake in UiPath by 46.0% during the first quarter.
Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after acquiring an additional 639 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.
About UiPath ( Get Free Report UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Featured Articles Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.
com's FREE daily email newsletter ..
